Cole Schotz Advises CoImmune, Inc. in Merger with Formula Pharmaceuticals, Inc.

April 30, 2020Attorney: Roger M. Iorio
Cole Schotz P.C. represented CoImmune, Inc. in a merger with Formula Pharmaceuticals, Inc., bringing together two therapeutic immuno-oncology platforms. Formula Pharmaceuticals merged into CoImmune, with CoImmune as the surviving company. The merger was also accompanied by a $6 million lead investment in CoImmune’s Series A Financing to fund the CAR-CIK program.

CoImmune, a U.S.-based company focused on the development and manufacture of cell-based therapeutics to treat unmet medical needs, will use the newly acquired technology, CAR-CIK (cytokine-induced killer cells), for clinical development in acute lymphoblastic leukemia. A press release with further details can be viewed here.

Cole Schotz member Roger Iorio advised CoImmune, Inc., in connection with the merger and the $6 million lead investment.

Hosted on the FirmWise platform.

© Cole Schotz P.C.


The materials on this site have been prepared by Cole Schotz P.C. for general informational purposes only and are not intended to constitute legal advice. Viewers should not act upon this information without seeking professional counsel on the specific facts and circumstances in question from an attorney licensed in their jurisdiction. Use of this site does not create an attorney-client relationship between the user and Cole Schotz or any lawyer(s) within the firm. Any information sent to Cole Schotz or its lawyers through this site will not be treated as confidential and is not protected by the attorney-client privilege.

© Cole Schotz P.C.

Attorney Advertising

This website is an advertisement for a law firm. Statements and previous outcomes do not imply similar results in your matters.

© Cole Schotz P.C.


Thank you for your interest in our publication. Please fill out below and a copy will be sent to your email address.


For Important Legal Updates and Resources on the Coronavirus Click Here.